November 22, 2024
Dyadic receives grant from Gates Foundation for RSV antibody development
Dyadic International has received a $3m grant from the Bill & Melinda Gates Foundation to develop monoclonal antibodies (mAbs) for the treatment of respiratory syncytial virus (RSV) and malaria.